DEWB continues to expand investment business in first half of 2008

- Investment activity expanded

- Further successful development of portfolio companies

- Repayment of bank liabilities concluded

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

balance

Jena, 7 August 2008 (euro adhoc) - Deutsche Effecten- und
Wechsel-Beteiligungsgesellschaft AG, (DEWB), Jena, today published
its financial results for the first half of 2008. In the first six
months of the current fiscal year the focus of activities was on new
investments and the systematic development of the portfolio
companies; as planned, there was no sale of holdings. Accordingly
earnings from operating activities (EBIT), at -0,7 million Euros,
came in at the same level as in the first half 2007. The result after
taxes improved slightly, to -0.7 million Euros (H1t half 2007: -0.8
million Euros). Primarily due to the repayment of the bank
liabilities of 5.0 million Euros, the balance sheet total as at 30
June 2008 reduced to 66.1 million Euros. Thus since 2005 DEWB has
reduced debts by 50.9 million Euros. Cash decreased to 10 million
Euros, due to both the reduction of the loan and to investments in
the portfolio, compared to 31 December 2007. Shareholders´ equity
fell slightly to 45.4 million Euros due to the result for the period.
The Net Asset Value (NAV) per share was 2.98 Euro (31 December 2007:
3.03 Euro/share), at a current DEWB share price of 2.35 Euro (6
August 2008).

Investments expanded markedly In April DEWB took a stake in two
promising companies within its investment focus on photonics and
sensor systems: Nanda Technologies GmbH, Unterschleissheim, develops
and produces optical inspection equipment for process controls in the
semiconductor manufacturing area. Based on a new optical design
combined with innovative image processing, Nandas product has the
potential to revolutionize quality control in the field of
semiconductor manufacture. Nanotron Technologies GmbH, Berlin, is a
leader in the development and the sale of wireless sensor networks as
well as solutions for radio-based communication and object
localisation. With its own patented transmission systems,
substantially superior to that of competing products, Nanotron shows
above-average growth potential.

As at 30 June 2008 DEWB holds 12 investments. The valuation of the
portfolio in the balance sheet amounts to 48.4 million Euros and has
increased substantially compared with 31 December 2007 (40.6 million
Euros). In the first half of 2008, DEWB invested 7.9 million Euros in
total. The share taken by photonics and sensor systems thereby rose
to 58 percent.

KSW Microtec successfully implements strategy The portfolio companies
of DEWB have developed well, despite signs of gloom in the economy
overall, posting growth in incoming orders. KSW Microtec AG has
pressed ahead consistently with the extension of its product
portfolio, thus effecting market entry into business sectors with
strong margins. KSW, ranking amongst the leading manufacturers of
RFID components worldwide, thereby seeks to gain further market
shares, with increasing profitability. "KSW´s strategy is bearing its
first fruits. Other companies in the market are also increasingly
convinced by the company´s positioning. Thus the recently-announced
commitment to DEWB made by RFID investor Bluehill demonstrates the
increased level of interest in KSW from investors and competitors",
Bertram Köhler, Member of the Management Board of DEWB, remarked on
the development at KSW.

NOXXON Pharma gains a further cooperation partner The portfilio
company NOXXON Pharma AG, developer of active agents based on
proprietary spiegelmer technology, concluded a cooperation agreement
with the US pharmaceutical giant Eli Lilly in the first half of the
current fiscal year. Within this contract NOXXON is granting Eli
Lilly an exclusive worldwide licence for a pre-clinical spiegelmer
against migraine and and will use its Spiegelmer technology to
identify follow-on inhibitors. Eli Lilly is taking over the
pre-clinical and clinical development of the molecules identified, as
well as the worldwide commercialisation of the products emerging from
this work. In addition to receiving an advance payment and further
milestone-dependent remunerations, NOXXON is eligible to earn
royalties on worldwide sales of products commercialized by Lilly as a
result of this collaboration. Eli Lilly is the fourth large
international pharmaceutical company, in addition to Pfizer, Dow
Chemical and Roche, to recognize the potential of NOXXON and position
itself accordingly within the scope of cooperation agreements.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

DEWB AG

Marco Scheidler

Leutragraben 1

Germany, 07743 Jena

Tel: +49 (0) 3641 573 3600

Fax: +49 (0) 3641 573 3610

E-Mail: ir@dewb-vc.com

www.dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse München / free trade